Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of Chronic Kidney Disease Stages 1–3

Slide: 27 of 29

Gaps in Knowledge

The systematic review identified areas where clear evidence is not available:

  • Whether clinical outcomes are improved from systematic screening for CKD in patients at high risk for developing CKD (e.g., patients with diabetes, hypertension, or CV disease) or systematic CKD monitoring for worsened kidney function or damage, especially in patients with CKD who also have hypertension, diabetes, or CV disease

  • If one-time measures of albuminuria or eGFR have the specificity and sensitivity to diagnose persistent CKD or CKD progression
  • Whether the clinical outcome benefits differ for a specific treatment between patients with recently worsened kidney function or damage (as detectable by monitoring) when compared with those with stable CKD
  • The long-term impact of treatment on clinical outcomes
  • The impact of dietary intervention or intensification of treatment (e.g., tight vs. standard blood pressure control, high vs. standard statin dose) on clinical outcomes for patients with CKD stages 1–3

Abbreviations:
CKD = chronic kidney disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate